The market is focused on Amgen's legacy drugs, but one number shows a new, faster-growing core business is already taking ...

Amgen Inc. (NASDAQ:AMGN) is one of the 7 Best Longevity Stocks to Buy Now. On June 7, 2026, Amgen Inc. (NASDAQ:AMGN) ...

Key Points Interested in Amgen Inc.? Here are five stocks we like better. Amgen said its strong first-quarter results support ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Amgen’s up-to-$2.5 billion acquisition of the antibody specialist Teneobio is costing the California drugmaker once again. | ...

An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing with the FDA which ...

After the FDA flagged patient deaths linked to Amgen's rare disease drug Tavneos and called for its voluntary removal, the ...

Amgen is developing monthly GLP-1 injections aimed at improving convenience and long-term adherence for patients.

Amgen raked in $8.5 billion during the third quarter, a 23% jump from the same period last year. Excluding contributions from Horizon, the growth rate was 8%. (Photo by Mario Tama/Getty Images) It’s ...

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.

Amgen subsidiary Teneobio must ‌pay biotech company Harbour Antibodies $20.2 million in damages for infringing a patent ...